中国快讯 (China Crunch) 为中国读者提供及时的加密新闻、市场洞察和监管动态。
WuXi Biologics Forecasts 46 Percent Profit Surge as Integrated Drug Strategy Drives Growth
WuXi Biologics has projected a sharp increase in full year earnings for 2025, signaling renewed momentum for China’s leading biologics contract development and manufacturing organization. The company expects profit attributable to equity shareholders to rise by 46.3 percent to approximately 4.91 billion yuan,